PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trialAndrea Necchi, Filippo de Braud, Patrizia Giannatempo et al.|Investigational New Drugs|2014Cited by 54
Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosisMarco Ladetto, Corrado Tarella, Caterina Patti et al.|Journal of Clinical Oncology|2007Cited by 2